Biomarkers for parkinsonian disorders in CNS-originating extracellular vesicles

中枢神经系统来源的细胞外囊泡中帕金森病的生物标志物

基本信息

  • 批准号:
    10662918
  • 负责人:
  • 金额:
    $ 237.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

Summary Many cases of Parkinson’s disease, and even more so atypical parkinsonian disorders, are misdiagnosed. Misdiagnosis not only causes high stress and anxiety to patients, their families, and their caregivers, but also is a major impediment to development of effective therapy for these diseases. Recently, we have demonstrated that the α-synuclein concentration in extracellular vesicles (EVs) immunoprecipitated from serum or plasma using oligodendroglial and neuronal markers, and in particular the ratio between the α-synuclein concentrations in the two types of EVs, is a sensitive biomarker for distinguishing between Parkinson’s disease and multiple system atrophy. This liquid biopsy approach requires only a minimally invasive blood draw and could lead to a major advancement in developing diagnostic tests for these diseases. Here, we propose to build upon these recent findings by constructing a biomarker panel, including several additional candidate markers, and apply the panel to two additional atypical parkinsonian syndromes—progressive supranuclear palsy and corticobasal syndrome. Serum samples for the study will be obtained from several national biorepositories as well as collected locally, prospectively, in expert clinics. The study design emphasizes biomarker analysis within the first two years of diagnosis, and in prodromal synucleinopathy, to test the utility of the biomarker panel when it is most needed. An additional goal of the project is to develop methodology for validating the cellular origin of the EVs, an urgent unmet need in the field. Success of the project will lead both to an advancement of research on biomarkers for CNS diseases using a minimally invasive liquid biopsy that can be translated into clinical use in the near future.
总结

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Recent advances and future therapy development for Alzheimer's disease and related disorders.
阿尔茨海默病及相关疾病的最新进展和未来治疗发展。
  • DOI:
    10.4103/1673-5374.391182
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Hong,Megan;Bitan,Gal
  • 通讯作者:
    Bitan,Gal
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GAL BITAN其他文献

GAL BITAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GAL BITAN', 18)}}的其他基金

Can diagnostic biomarkers for parkinsonian syndromes be measured in postmortem blood samples?
可以在死后血液样本中测量帕金森综合症的诊断生物标志物吗?
  • 批准号:
    10572535
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
Investigation of the Effect of Structural Modifications of Tau on Assembly State and Seeding
Tau 结构修饰对组装状态和播种影响的研究
  • 批准号:
    10241797
  • 财政年份:
    2017
  • 资助金额:
    $ 237.47万
  • 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
  • 批准号:
    9267131
  • 财政年份:
    2015
  • 资助金额:
    $ 237.47万
  • 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
  • 批准号:
    9139393
  • 财政年份:
    2015
  • 资助金额:
    $ 237.47万
  • 项目类别:
Misfolded protein clearance enhancers for Alzheimers therapy
用于治疗阿尔茨海默病的错误折叠蛋白清除增强剂
  • 批准号:
    9331297
  • 财政年份:
    2015
  • 资助金额:
    $ 237.47万
  • 项目类别:
Novel Specific Ligands for ABeta Oligomers
Aβ 低聚物的新型特异性配体
  • 批准号:
    7296776
  • 财政年份:
    2007
  • 资助金额:
    $ 237.47万
  • 项目类别:
Novel Specific Ligands for ABeta Oligomers
Aβ 低聚物的新型特异性配体
  • 批准号:
    7486743
  • 财政年份:
    2007
  • 资助金额:
    $ 237.47万
  • 项目类别:
DEVELOPMENT AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
淀粉样 B 蛋白寡聚化抑制剂
  • 批准号:
    7112795
  • 财政年份:
    2006
  • 资助金额:
    $ 237.47万
  • 项目类别:
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
B 淀粉样蛋白寡聚化抑制剂的开发
  • 批准号:
    8114005
  • 财政年份:
  • 资助金额:
    $ 237.47万
  • 项目类别:
DEVELOPMENT OF AMYLOID B-PROTEIN OLIGOMERIZATION INHIBITORS
B 淀粉样蛋白寡聚化抑制剂的开发
  • 批准号:
    7663803
  • 财政年份:
  • 资助金额:
    $ 237.47万
  • 项目类别:

相似海外基金

A study for cross borders Indonesian nurses and care workers: Case of Japan-Indonesia Economic Partnership Agreement
针对跨境印度尼西亚护士和护理人员的研究:日本-印度尼西亚经济伙伴关系协定的案例
  • 批准号:
    22KJ0334
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
NSF-NOAA Interagency Agreement (IAA) for the Global Oscillations Network Group (GONG)
NSF-NOAA 全球振荡网络组 (GONG) 机构间协议 (IAA)
  • 批准号:
    2410236
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Cooperative Agreement
Conditions for U.S. Agreement on the Closure of Contested Overseas Bases: Relations of Threat, Alliance and Base Alternatives
美国关于关闭有争议的海外基地协议的条件:威胁、联盟和基地替代方案的关系
  • 批准号:
    23K18762
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
MSI Smart Manufacturing Data Hub – Open Calls Grant Funding Agreement
MSI 智能制造数据中心 – 公开征集赠款资助协议
  • 批准号:
    900240
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Collaborative R&D
Challenges of the Paris Agreement Exposed by the Energy Shift by External Factors: The Case of Renewable Energy Policies in Japan, the U.S., and the EU
外部因素导致的能源转移对《巴黎协定》的挑战:以日本、美国和欧盟的可再生能源政策为例
  • 批准号:
    23H00770
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Continuation of Cooperative Agreement between U.S. Food and Drug Administration and S.C. Department of Health and Environmental Control (DHEC) for MFRPS Maintenance.
美国食品和药物管理局与南卡罗来纳州健康与环境控制部 (DHEC) 继续签订 MFRPS 维护合作协议。
  • 批准号:
    10829529
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
National Ecological Observatory Network Governing Cooperative Agreement
国家生态观测站网络治理合作协议
  • 批准号:
    2346114
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Cooperative Agreement
The Kansas Department of Agriculture's Flexible Funding Model Cooperative Agreement for MFRPS Maintenance, FPTF, and Special Project.
堪萨斯州农业部针对 MFRPS 维护、FPTF 和特别项目的灵活资助模式合作协议。
  • 批准号:
    10828588
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
Robust approaches for the analysis of agreement between clinical measurements: development of guidance and software tools for researchers
分析临床测量之间一致性的稳健方法:为研究人员开发指南和软件工具
  • 批准号:
    MR/X029301/1
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Research Grant
FER (H&L) AMR PACE (A-0438) grant funding agreement
费率(H
  • 批准号:
    107541
  • 财政年份:
    2023
  • 资助金额:
    $ 237.47万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了